Philadelphia, PA—A breath-powered intranasal powder form of sumatriptan produces fast and sustained relief of migraine, according to the results of a phase 3, placebo-controlled trial presented at the 2014 American Academy of Neurology meeting.
Blinding of patients to their assigned treatment (active or placebo) is a standard procedure in clinical trials to assess the “true” efficacy of the active drug. But what happens when patients are certain whether they are receiving active treatment or placebo?
The annual direct medical costs of patients with chronic migraine approach $5000, and the costs associated with lost productivity exceed $3000 annually.
Migraine is the third most common medical condition and the eighth leading cause of disability worldwide, according to the World Health Organization; yet, migraines are still underdiagnosed and undertreated. The misdiagnosis of migraines is partly to blame for patients not receiving optimal care.
Philadelphia, PA—Two investigational monoclonal antibodies against the calcitonin gene-related peptide (CGRP) proved safe and effective at preventing migraine in a pair of phase 2, placebo-­controlled, proof-of-concept trials, researchers reported at the 2014 American Academy of Neurology meeting.

Results 1 - 5 of 5
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology